<?xml version='1.0' encoding='utf-8'?>
<document id="12766253"><sentence text="Avasimibe induces CYP3A4 and multiple drug resistance protein 1 gene expression through activation of the pregnane X receptor."><entity charOffset="0-9" id="DDI-PubMed.12766253.s1.e0" text="Avasimibe" /></sentence><sentence text="In vitro and clinical studies were conducted to characterize the potential of avasimibe, an acyl-CoA/cholesterol acyltransferase inhibitor to cause drug-drug interactions"><entity charOffset="78-87" id="DDI-PubMed.12766253.s2.e0" text="avasimibe" /><entity charOffset="101-112" id="DDI-PubMed.12766253.s2.e1" text="cholesterol" /><pair ddi="false" e1="DDI-PubMed.12766253.s2.e0" e2="DDI-PubMed.12766253.s2.e0" /><pair ddi="false" e1="DDI-PubMed.12766253.s2.e0" e2="DDI-PubMed.12766253.s2.e1" /></sentence><sentence text=" Clinically, 3- and 6-fold increases in midazolam (CYP3A4 substrate) oral clearance were observed after 50 and 750 mg of avasimibe daily for 7 days, respectively" /><sentence text=" A 40% decrease in digoxin (P-glycoprotein substrate) area under the curve was observed with 750 mg of avasimibe daily for 10 days"><entity charOffset="19-26" id="DDI-PubMed.12766253.s4.e0" text="digoxin" /></sentence><sentence text=" In vitro studies were conducted to define the mechanisms of these interactions" /><sentence text=" Induction was observed in CYP3A4 activity and immunoreactive protein (EC50 of 200-400 nM) in primary human hepatocytes treated with avasimibe"><entity charOffset="133-142" id="DDI-PubMed.12766253.s6.e0" text="avasimibe" /></sentence><sentence text=" Rifampin treatment yielded similar results"><entity charOffset="1-9" id="DDI-PubMed.12766253.s7.e0" text="Rifampin" /></sentence><sentence text=" Microarray analysis revealed avasimibe (1 microM) increased CYP3A4 mRNA 20-fold, compared with a 23-fold increase with 50 microM rifampin"><entity charOffset="130-138" id="DDI-PubMed.12766253.s8.e0" text="rifampin" /></sentence><sentence text=" Avasimibe induced P-glycoprotein mRNA by about 2-fold and immunoreactive protein in a dose-dependent manner" /><sentence text=" Transient transfection assays showed that avasimibe is a potent activator of the human pregnane X receptor (hPXR) and more active than rifampin on an equimolar basis"><entity charOffset="136-144" id="DDI-PubMed.12766253.s10.e0" text="rifampin" /></sentence><sentence text=" Drug-drug interaction studies for CYP3A4 using pooled human hepatic microsomes and avasimibe at various concentrations, revealed IC50 values of 20" /><sentence text="7, 1" /><sentence text="6, and 3" /><sentence text="1 microM using testosterone, midazolam, and felodipine as probe substrates, respectively"><entity charOffset="15-27" id="DDI-PubMed.12766253.s14.e0" text="testosterone" /><entity charOffset="29-38" id="DDI-PubMed.12766253.s14.e1" text="midazolam" /><entity charOffset="44-54" id="DDI-PubMed.12766253.s14.e2" text="felodipine" /><pair ddi="false" e1="DDI-PubMed.12766253.s14.e0" e2="DDI-PubMed.12766253.s14.e0" /><pair ddi="false" e1="DDI-PubMed.12766253.s14.e0" e2="DDI-PubMed.12766253.s14.e1" /><pair ddi="false" e1="DDI-PubMed.12766253.s14.e0" e2="DDI-PubMed.12766253.s14.e2" /><pair ddi="false" e1="DDI-PubMed.12766253.s14.e1" e2="DDI-PubMed.12766253.s14.e1" /><pair ddi="false" e1="DDI-PubMed.12766253.s14.e1" e2="DDI-PubMed.12766253.s14.e2" /></sentence><sentence text=" Our results indicate that avasimibe causes clinically significant drug-drug interactions through direct activation of hPXR and the subsequent induction of its target genes CYP3A4 and multiple drug resistance protein 1" /><sentence text="" /></document>